Aion Therapeutic Stock Fundamentals
| ANTCF Stock | USD 0.03 0.02 185.71% |
Aion Therapeutic fundamentals help investors to digest information that contributes to Aion Therapeutic's financial success or failures. It also enables traders to predict the movement of Aion Pink Sheet. The fundamental analysis module provides a way to measure Aion Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aion Therapeutic pink sheet.
Aion |
Aion Therapeutic Company Shares Owned By Insiders Analysis
Aion Therapeutic's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aion Therapeutic Shares Owned By Insiders | 17.68 % |
Most of Aion Therapeutic's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aion Therapeutic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 17.682% of Aion Therapeutic are shares owned by insiders. This is 16.48% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by insiders for all United States stocks is 75.24% lower than that of the firm.
Aion Therapeutic Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aion Therapeutic's current stock value. Our valuation model uses many indicators to compare Aion Therapeutic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aion Therapeutic competition to find correlations between indicators driving Aion Therapeutic's intrinsic value. More Info.Aion Therapeutic is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aion Therapeutic's earnings, one of the primary drivers of an investment's value.Aion Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aion Therapeutic's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aion Therapeutic could also be used in its relative valuation, which is a method of valuing Aion Therapeutic by comparing valuation metrics of similar companies.Aion Therapeutic is currently under evaluation in shares owned by insiders category among its peers.
Aion Fundamentals
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 147.3 M | |||
| Shares Owned By Insiders | 17.68 % | |||
| Price To Book | 5.77 X | |||
| Gross Profit | (1.5 K) | |||
| EBITDA | (3.68 M) | |||
| Net Income | (3.82 M) | |||
| Cash And Equivalents | 1.85 K | |||
| Total Debt | 643.8 K | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 0.15 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.35 M) | |||
| Earnings Per Share | (0.04) X | |||
| Beta | 0.29 | |||
| Market Capitalization | 1.47 M | |||
| Total Asset | 150.14 K | |||
| Z Score | -78.0 | |||
| Net Asset | 150.14 K |
About Aion Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aion Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aion Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aion Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Aion Therapeutic Inc., a pharmaceutical company, offer medical cannabis products in Canada. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada. Aion Therapeutic is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Aion Pink Sheet
Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.